What is ANEB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ANEB?

P/E (TTM) is n/a and 52-week range is $0.00 to $2.76 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ANEB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ANEB?

The company profile lists net income (TTM) near -$8M, EPS (TTM) near -$0.19 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Anebulo Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Lakeway, Texas, US, 40.8M shares outstanding, ISIN US0345691036 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Anebulo Pharmaceuticals Inc

$ANEB

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. The company is headquartered in Lakeway, Texas and currently employs 2 full-time employees. The company went IPO on 2021-05-07. The company is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. The company is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.

Employees

Website

www.anebulo.com/

IPO

2021-05-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

OTC MARKETS

ISIN

US0345691036

Headquarters

Lakeway, Texas, US

Shares outstanding

40.8M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

0.00%

Browse other companiesFree AI scores and summaries for more stocks